RecruitingPhase 3NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OSE Immunotherapeutics
- Intervention
- OSE2101(drug)
- Enrollment
- 363 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Clinical Research Advisors, LLC, Beverly Hills, California, United States
- Clinical Research Advisors - Encino, Encino, California, United States
- Clinical Research Advisors - West Hollywood, Los Angeles, California, United States
- Clinical Research Advisors - Korea Town, Los Angeles, California, United States
- SCL Health - Saint Joseph Hospital Cancer Center, Littleton, Colorado, United States
- Lutheran Medical Center - Cancer Centers of Colorado, Wheat Ridge, Colorado, United States
- Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States
- Comprehensive Hematology Oncology - Bradenton Clinic, Bradenton, Florida, United States
- Comprehensive Hematology Oncology - Brandon Clinic, Brandon, Florida, United States
- Cancer Specialists of North Florida - Fleming Island, Fleming Island, Florida, United States
- Cancer Specialists of North Florida - Riverside, Jacksonville, Florida, United States
- Cancer Specialists of North Florida Southside, Jacksonville, Florida, United States
- Cancer Specialists of North Florida - Northside, Jacksonville, Florida, United States
- Cancer Specialists of North Florida - Southpoint, Jacksonville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Exystat · Genome Diagnostics (GenDx)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06472245 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →